PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Schneider, H.* ; Sarkis, A.L.* ; Sturm, L.* ; Britz, V.* ; Lechner, A. ; Potzel, A. ; Müller, L.M.* ; Heinrich, D.A.* ; Künzel, H.* ; Nowotny, H.F.* ; Seiter, T.M.* ; Kunz, S.* ; Bidlingmaier, M.* ; Reincke, M.* ; Adolf, C.*

Moderate dietary salt restriction improves blood pressure and mental well-being in patients with primary aldosteronism: The salt CONNtrol trial.

J. Intern. Med. 294, 47-57 (2023)
Verlagsversion DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
BACKGROUND: Primary aldosteronism (PA) is a frequent cause of hypertension. Aldosterone excess together with high dietary salt intake aggravates cardiovascular damage, despite guideline-recommended mineralocorticoid receptor antagonist (MRA) treatment. OBJECTIVES: To investigate the antihypertensive impact of a moderate dietary salt restriction and associated physiological changes, including mental well-being. METHODS: A total of 41 patients with PA on a stable antihypertensive regimen-including MRA-followed a dietary salt restriction for 12 weeks with structured nutritional training and consolidation by a mobile health app. Salt intake and adherence were monitored every 4 weeks using 24-h urinary sodium excretion and nutrition protocols. Body composition was assessed by bioimpedance analysis and mental well-being by validated questionnaires. RESULTS: Dietary salt intake significantly decreased from 9.1 to 5.2 g/d at the end of the study. In parallel, systolic (130 vs. 121 mm Hg) and diastolic blood pressure (BP) (84 vs. 81 mm Hg) improved significantly. Patients' aptitude of estimating dietary salt content was refined significantly (underestimation by 2.4 vs. 1.4 g/d). Salt restriction entailed a significant weight loss of 1.4 kg, improvement in pulse pressure (46 vs. 40 mm Hg) and normalization of depressive symptoms (PHQD scale, p < 0.05). Salt restriction, cortisol after dexamethasone suppression test and dosage of renin-angiotensin-aldosterone-system (RAAS) blockers were independently associated with BP reduction. CONCLUSION: A moderate restriction of dietary salt intake in patients with PA substantially reduces BP and depressive symptoms. Moreover, the findings underline that a sufficient RAAS blockade seems to augment the effects of salt restriction on BP and cardiovascular risk.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
11.100
0.000
2
2
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Aldosterone ; Cardiovascular Risk ; Hypertension ; Mineralocorticoid Receptor Antagonist ; Salt Restriction ; Salt Sensitivity ; Sodium; Sensitive Neurons; Solitary Tract; Reduction; Mortality; Nucleus
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 0954-6820
e-ISSN 1365-2796
Zeitschrift Journal of Internal Medicine
Quellenangaben Band: 294, Heft: 1, Seiten: 47-57 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort 111 River St, Hoboken 07030-5774, Nj Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Experimental Genetics (IEG)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-521500-002
Förderungen German Center for Diabetes Research
LMU Klinikum
Helmholtz Zentrum Muenchen
Else Kroener-Fresenius Stiftung
FoeFoLe
Else Kroener-Fresenius-Stiftung
Eva Luise und Horst Koehler Stiftung AMP
Deutsche Forschungsgemeinschaft (DFG) (within the CRC/Transregio 205/2 "The Adrenal: Central Relay in Health and Disease" within the Clinician Scientist Program In Vascular MEdicine (PRIME)
European Research Council (ERC) under the European Union
Else Kroener-Fresenius Stiftung in support of the German Conn's Registry-Else-Kroener Hyperaldosteronism Registry
DOI 10.1111/joim.13618
WOS ID 000954308600001
Scopus ID 85150909446
PubMed ID 36945842
Erfassungsdatum 2023-10-06
[➜Korrektur melden]